Study Design Characteristics and Endpoints for Enriched Enrollment Randomized Withdrawal Trials for Chronic Pain Patients: A Systematic Review

References

• Moore RA, Wiffen PJ, Eccleston C, et al. Systematic review of enriched enrolment, randomised withdrawal trial designs in chronic pain: a new framework for design and reporting. Pain. 2015;156(8):1382–1395. doi:10.1097/j.pain.0000000000000088
   PubMed Web of Science ®Google Scholar
• Katz N. Enriched enrollment randomized withdrawal trial designs of analgesics: focus on methodology. Clin J Pain. 2009;25(9):797–807. doi:10.1097/AJP.0b013e3181b12dec
   PubMed Web of Science ®Google Scholar
• Campbell J, King NB. ‘Unsettling circularity’: clinical trial enrichment and the evidentiary politics of chronic pain. BioSocieties. 2017;12:191–216. doi:10.1057/biosoc.2016.7
   Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Peirce-Sandner S, et al. Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain. 2010;149(2):177–193. doi:10.1016/j.pain.2010.02.018
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113(1–2):9–19. doi:10.1016/j.pain.2004.09.012
   PubMed Web of Science ®Google Scholar
• Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003;106(3):337–345. doi:10.1016/j.pain.2003.08.001
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105–121. doi:10.1016/j.jpain.2007.09.005
   PubMed Web of Science ®Google Scholar
• Meske DS, Lawal OD, Elder H, Langberg V, Paillard F, Katz N. Efficacy of opioids versus placebo in chronic pain: a systematic review and meta-analysis of enriched enrollment randomized withdrawal trials. J Pain Res. 2018;11:923–934. doi:10.2147/JPR.S160255
   PubMed Web of Science ®Google Scholar
• Meske DS, Vaughn BJ, Kopecky EA, Katz N. Number of clinical trial study sites impacts observed treatment effect size: an analysis of randomized controlled trials of opioids for chronic pain. J Pain Res. 2019;12:3161–3165. doi:10.2147/JPR.S201751
   PubMed Web of Science ®Google Scholar
• Yamato TP, Maher CG, Saragiotto BT, et al. Comparison of effect sizes between enriched and nonenriched trials of analgesics for chronic musculoskeletal pain: a systematic review. Br J Clin Pharmacol. 2017;83(11):2347–2355. doi:10.1111/bcp.13350
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Haroutounian S, Baron R, et al. Neuropathic pain clinical trials: factors associated with decreases in estimated drug efficacy. Pain. 2018;159(11):2339–2346. doi:10.1097/j.pain.0000000000001340
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi:10.1136/bmj.b2535
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Savović J, Page MJ, et al. Chapter 8: assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0. Cochrane; 2019.
   Google Scholar
• Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310(6977):452–454. doi:10.1136/bmj.310.6977.452
   PubMed Web of Science ®Google Scholar
• Schober P, Vetter TR. Meta-analysis in clinical research. Anesth Analg. 2020;131(4):1090–1091. doi:10.1213/ANE.0000000000005001
   PubMed Web of Science ®Google Scholar
• Schober P, Vetter TR. Nonparametric statistical methods in medical research. Anesth Analg. 2020;131(6):1862–1863. doi:10.1213/ANE.0000000000005101
   PubMed Web of Science ®Google Scholar
• Rauck RL, Potts J, Xiang Q, Tzanis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-naive patients with moderate to severe chronic low back pain. Postgrad Med. 2016;128(1):1–11. doi:10.1080/00325481.2016.1128307
   PubMed Web of Science ®Google Scholar
• Gimbel J, Spierings EL, Katz N, Xiang Q, Tzanis E, Finn A. Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a Phase 3, enriched enrollment, randomized withdrawal study. Pain. 2016;157(11):2517–2526. doi:10.1097/j.pain.0000000000000670
   PubMed Web of Science ®Google Scholar
• Rauck RL, Hale ME, Bass A, et al. A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment. Pain. 2015;156(9):1660–1669. doi:10.1097/j.pain.0000000000000230
   PubMed Web of Science ®Google Scholar
• Katz N, Kopecky EA, O’Connor M, Brown RH, Fleming AB. A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain. Pain. 2015;156(12):2458–2467. doi:10.1097/j.pain.0000000000000315
   PubMed Web of Science ®Google Scholar
• Hale ME, Zimmerman TR, Eyal E, Malamut R. Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain. J Opioid Manag. 2015;11(6):507–518. doi:10.5055/jom.2015.0304
   PubMedGoogle Scholar
• Hale ME, Laudadio C, Yang R, Narayana A, Malamut R. Efficacy and tolerability of a hydrocodone extended-release tablet formulated with abuse-deterrence technology for the treatment of moderate-to-severe chronic pain in patients with osteoarthritis or low back pain. J Pain Res. 2015;8:623–636. doi:10.2147/JPR.S83930
   PubMed Web of Science ®Google Scholar
• Wen W, Sitar S, Lynch SY, He E, Ripa SR. A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain. Expert Opin Pharmacother. 2015;16(11):1593–1606. doi:10.1517/14656566.2015.1060221
   PubMed Web of Science ®Google Scholar
• Raskin P, Huffman C, Toth C, et al. Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial. Clin J Pain. 2014;30(5):379–390. doi:10.1097/AJP.0b013e31829ea1a1
   PubMed Web of Science ®Google Scholar
• Vinik AI, Shapiro DY, Rauschkolb C, et al. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care. 2014;37(8):2302–2309. doi:10.2337/dc13-2291
   PubMed Web of Science ®Google Scholar
• Rauck RL, Nalamachu S, Wild JE, et al. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study. Pain Med. 2014;15(6):975–985. doi:10.1111/pme.12377
   PubMed Web of Science ®Google Scholar
• Toth C, Mawani S, Brady S, et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain. 2012;153(10):2073–2082. doi:10.1016/j.pain.2012.06.024
   PubMed Web of Science ®Google Scholar
• Steiner DJ, Sitar S, Wen W, et al. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study. J Pain Symptom Manage. 2011;42(6):903–917. doi:10.1016/j.jpainsymman.2011.04.006
   PubMed Web of Science ®Google Scholar
• Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27(1):151–162. doi:10.1185/03007995.2010.537589
   PubMed Web of Science ®Google Scholar
• Gilron I, Wajsbrot D, Therrien F, Lemay J. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial. Clin J Pain. 2011;27(3):185–193. doi:10.1097/AJP.0b013e3181fe13f6
   PubMed Web of Science ®Google Scholar
• Hale M, Khan A, Kutch M, Li LS. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. Curr Med Res Opin. 2010;26(6):1505–1518. doi:10.1185/03007995.2010.484723
   PubMed Web of Science ®Google Scholar
• Katz N, Hale M, Morris D, Stauffer J. Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgrad Med. 2010;122(4):112–128. doi:10.3810/pgm.2010.07.2179
   PubMed Web of Science ®Google Scholar
• Katz N, Rauck R, Ahdieh H, et al. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res Opin. 2007;23(1):117–128. doi:10.1185/030079906X162692
   PubMed Web of Science ®Google Scholar
• Hale ME, Ahdieh H, Ma T, Rauck R. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain. 2007;8(2):175–184. doi:10.1016/j.jpain.2006.09.011
   PubMed Web of Science ®Google Scholar
• Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus Acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol. 1999;26(4):862–869.
   PubMed Web of Science ®Google Scholar
• Kawamata M, Iseki M, Kawakami M, et al. Efficacy and safety of controlled-release oxycodone for the management of moderate-to-severe chronic low back pain in Japan: results of an enriched enrollment randomized withdrawal study followed by an open-label extension study. J Pain Res. 2019;12:363–375. doi:10.2147/JPR.S179110
   PubMed Web of Science ®Google Scholar
• Huffman CL, Goldenberg JN, Weintraub J, et al. Efficacy and safety of once-daily controlled-release pregabalin for the treatment of patients with postherpetic neuralgia: a double-blind, enriched enrollment randomized withdrawal, placebo-controlled trial. Clin J Pain. 2017;33(7):569–578. doi:10.1097/AJP.0000000000000445
   PubMed Web of Science ®Google Scholar
• Arai T, Kashimoto Y, Ukyo Y, Tominaga Y, Imanaka K. Two placebo-controlled, randomized withdrawal studies to evaluate the fentanyl 1 day patch in opioid-naive patients with chronic pain. Curr Med Res Opin. 2015;31(12):2207–2218. doi:10.1185/03007995.2015.1092127
   PubMed Web of Science ®Google Scholar
• Arnold LM, Arsenault P, Huffman C, et al. Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a Phase III, double-blind, randomized withdrawal, placebo-controlled study. Curr Med Res Opin. 2014;30(10):2069–2083. doi:10.1185/03007995.2014.928275
   PubMed Web of Science ®Google Scholar
• Clauw DJ, Mease PJ, Palmer RH, Trugman JM, Wang Y. Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial. Arthritis Res Ther. 2013;15(4):R88. doi:10.1186/ar4268
   PubMed Web of Science ®Google Scholar
• Baron R, Freynhagen R, Tölle TR, et al. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain. 2010;150(3):420–427. doi:10.1016/j.pain.2010.04.013
   PubMed Web of Science ®Google Scholar
• Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136(3):419–431. doi:10.1016/j.pain.2008.02.027
   PubMed Web of Science ®Google Scholar
• Zakrzewska JM, Palmer J, Morisset V, et al. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. Lancet Neurol. 2017;16(4):291–300. doi:10.1016/S1474-4422(17)30005-4
   PubMed Web of Science ®Google Scholar
• McQuay HJ, Derry S, Moore RA, Poulain P, Legout V. Enriched enrolment with randomised withdrawal (EERW): time for a new look at clinical trial design in chronic pain. Pain. 2008;135(3):217–220. doi:10.1016/j.pain.2008.01.014
   PubMed Web of Science ®Google Scholar
• Furlan A, Chaparro LE, Irvin E, Mailis-Gagnon A. A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain. Pain Res Manag. 2011;16(5):337–351. doi:10.1155/2011/465281
   PubMed Web of Science ®Google Scholar
• Sommer C, Klose P, Welsch P, Petzke F, Häuser W. Opioids for chronic non-cancer neuropathic pain. An updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration. Eur J Pain. 2020;24(1):3–18. doi:10.1002/ejp.1494
   PubMed Web of Science ®Google Scholar
• Petzke F, Klose P, Welsch P, Sommer C, Häuser W. Opioids for chronic low back pain: an updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks of double-blind duration. Eur J Pain. 2020;24(3):497–517. doi:10.1002/ejp.1519
   PubMed Web of Science ®Google Scholar
• Schneider S, Junghaenel DU, Keefe FJ, Schwartz JE, Stone AA, Broderick JE. Individual differences in the day-to-day variability of pain, fatigue, and well-being in patients with rheumatic disease: associations with psychological variables. Pain. 2012;153(4):813–822. doi:10.1016/j.pain.2012.01.001
   PubMed Web of Science ®Google Scholar
• Bartley EJ, Robinson ME, Staud R. Pain and fatigue variability patterns distinguish subgroups of fibromyalgia patients. J Pain. 2018;19(4):372–381. doi:10.1016/j.jpain.2017.11.014
   PubMed Web of Science ®Google Scholar
• Gilron I, Carr DB, Desjardins PJ, Kehlet H. Current methods and challenges for acute pain clinical trials. Pain Rep. 2019;4(3):e647. doi:10.1097/PR9.0000000000000647
   PubMedGoogle Scholar
• Katz N, Paillard FC, Van Inwegen R. A review of the use of the number needed to treat to evaluate the efficacy of analgesics. J Pain. 2015;16(2):116–123. doi:10.1016/j.jpain.2014.08.005
   PubMed Web of Science ®Google Scholar
• Hewitt DJ, Ho TW, Galer B, et al. Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain. Pain. 2011;152(3):514–521. doi:10.1016/j.pain.2010.10.050
   PubMed Web of Science ®Google Scholar
• Altman DG. Practical Statistics for Medical Research. Boca Raton, FL: Chapman & Hall/CRC; 1999.
   Google Scholar
• Gilron I. Methodological issues associated with clinical trials in neuropathic pain. Expert Rev Clin Pharmacol. 2016;9(11):1399–1402. doi:10.1080/17512433.2016.1240029
   PubMed Web of Science ®Google Scholar
• National Research Council (US) Panel on Handling Missing Data in Clinical Trials. The prevention and treatment of missing data in clinical trials. Washington (DC): National Academies Press (US); 2010.
   Google Scholar